Growth hormone inhibits activation of phosphatidylinositol phospholipase C in adipose plasma membranes: evidence for a growth hormone-induced change in G protein function

Mitral and tricuspid annular velocities determined by Doppler tissue imaging in hypopituitary, growth hormone-deficient patients

BACKGROUND

The aim of this study is to determine systolic and diastolic velocity profiles of the left and right ventricles by tissue Doppler imaging (TDI) and to reveal the associations between TDI parameters and early atherosclerotic changes in adult hypopituitary patients with GH deficiency.

PATIENTS AND METHODS

The study group is composed of 16 hypopituitary, GH-deficient patients and 13 healthy controls. All patients had been receiving adequate substitution therapy other than GH at stable doses for at least 6 months. Conventional Doppler echocardiography and TDI of the mitral and tricuspid annulus were performed. Intima-media thickness (IMT) of the common carotid artery was calculated.

RESULTS

IMT was significantly higher in the hypopituitary group compared with controls (0.83 +/- 0.25 vs. 0.51 +/- 0.14 mm, p < 0.001). Hypopituitary patients had significantly lower peak early diastolic (Em) mitral annular velocity (11.2 +/- 3.0 vs. 13.9 +/- 2.8 cm/s, p < 0.05). Multiple regression analysis revealed that age was the only independent variable significantly associated with Em and IMT in the patients.

CONCLUSION

Diastolic abnormalities on TDI of the mitral annulus and early atherosclerotic changes occur concurrently in asymptomatic hypopituitary patients with GH deficiency. Aging may have a more deleterious effect on ventricular function and atherogenesis in this group of patients.

Growth hormone-induced diacylglycerol and ceramide formation via Galpha i3 and Gbeta gamma in GH4 pituitary cells. Potentiation by dopamine-D2 receptor activation

Growth hormone (GH) secretion is regulated by indirect negative feedback mechanisms. To address whether GH has direct actions on pituitary cells, lipid signaling in GH(4)ZR(7) somatomammotroph cells was examined. GH (EC(50) = 5 nm) stimulated diacylglycerol (DAG) and ceramide formation in parallel by over 10-fold within 15 min and persisting for >3 h. GH-induced DAG/ceramide formation was blocked by pertussis toxin (PTX) implicating G(i)/G(o) proteins and was potentiated 1.5-fold by activation of G(i)/G(o)-coupled dopamine-D2S receptors, which had no effect alone. Following PTX pretreatment, only PTX-resistant Galpha(i)3, not Galpha(o) or Galpha(i)2, rescued GH-induced DAG/ceramide signaling. GH-induced DAG/ceramide formation was also blocked in cells expressing Gbetagamma blocker GRK-ct. In GH(4)ZR(7) cells, GH induced phosphorylation of JAK2 and STAT5, which was blocked by PTX and mimicked by ceramide analogue C2-ceramide or sphingomyelinase treatment to increase endogenous ceramide. We conclude that in GH(4) pituitary cells, GH induces formation of DAG/ceramide via a novel Galpha(i)3/Gbetagamma-dependent pathway. This novel pathway suggests a mechanism for autocrine feedback regulation by GH of pituitary function.

Left ventricular diastolic function abnormalities in hypopituitary patients with GH deficiency: evidence for a subclinical cardiomyopathy

The aim of this study was to evaluate cardiac performance, in particular diastolic function, in adult patients with adulthood onset GH deficiency. The study group was composed of 19 GH deficient adult hypopituitary patients with at-least 3 additional pituitary hormone deficits and 19 age, sex and BMI matched healthy controls. Mean duration of hypopituitarism was 108.6 +/- 77.0 months. None of the patients and controls presented with or had previous diagnosis of concomitant diseases that could affect cardiac function. All hormone deficiencies, except for GH, were appropriately replaced in the patients. Left ventricular function and geometry were evaluated by two-dimensional, M-mode and Doppler echocardiography. Body composition was evaluated by bioelectrical impedance analysis. Not significant differences were observed with respect to left heart dimensions and left ventricular systolic function between patients and controls. Nevertheless 2 of the left ventricular diastolic function parameters, deceleration time and isovolumetric relaxation time, were significantly prolonged in the patients compared with controls (247.88 +/- 70.65 vs 143.26 +/- 31.70 milliseconds (ms) and 122.31 +/- 18.24 vs 89.47 +/- 12.12 ms respectively, p<0.001). Duration of hypopituitarism was significantly correlated with percent body fat mass (r=0.6119, p<0.01) and percent lean body mass (r=-0.5949, p<0.01). It is concluded that in adults affected by hypopituitarism, GH deficiency predominantly impairs diastolic function while systolic function at rest is spared. This observation might indicate a preclinical stage of a cardiomyopathy.

Exogenous growth hormone: a new therapy for dilated cardiomyopathy

Heart failure is an epidemic within the United States and, despite current medical therapy, carries a high mortality rate. Growth hormone and insulin-like growth factor-1 have known direct effects on the cardiovascular system. Improvement in contractility, reduction in wall stress, and increase in cardiac performance have been noted in animal experiments. Furthermore, preliminary data from human trials are encouraging. This report outlines the biology of growth hormone, the experimental and human data to support clinical trials of growth hormone treatment, and the outcome of trials reported to date.

Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions

GH, in the presence of glucocorticoid, produces a delayed increase in lipolysis in rat adipose tissue, but the biochemical mechanisms that account for this action have not been established. Other lipolytic agents rapidly activate adenylyl cyclase (AC) and the resulting production of cAMP initiates a chain of reactions that culminates in the activation of hormone-sensitive lipase. We compared responses of segments of rat epididymal fat or isolated adipocytes to 30 ng/ml GH and 0.1 microg/ml dexamethasone (Dex) with 0.1 ng/ml isoproterenol (ISO), which evoked a similar increase in lipolysis. All measurements were made during the fourth hour after the addition of GH+Dex or immediately after the addition of ISO to cells or tissues that had been preincubated for 3 h without hormone. Although no significant increases in cAMP were discernible in homogenates of GH+Dex-treated tissues, Rp-cAMPS (Rp-adenosine 3'5'-phosphothioate), a competitive inhibitor of cAMP, was equally effective in decreasing lipolysis induced by GH+Dex or ISO. The proportion of PKA that was present in the active form was determined by measuring the incorporation of 32P from [gamma-32P]ATP into kemptide in the absence and presence of saturating amounts of cAMP. GH+Dex and ISO produced similar increases in protein kinase A activity in tissue extracts. Treatment with GH+Dex did not change the total forskolin-stimulated AC present in either a crude membrane pellet sedimented at 16K x g or a less dense membrane pellet sedimented at 100K x g, but doubled the AC activity in the 16K pellet when assayed in the absence of forskolin. To evaluate possible effects on G proteins, pellets obtained from centrifugation of adipocyte homogenates at 16K x g and 100K x g were solubilized and subjected to PAGE and Western analysis. GH+Dex decreased Gi alpha2 by 44% (P < 0.02) in the 16K pellets and increased it by 52% (P < 0.01) in the 100K pellets. Gs alpha in the 16K pellet was unaffected by GH+Dex and was decreased (P < 0.05) in the 100K pellet. Sucrose density fractionation of the 16K pellets revealed a similar GH+Dex-dependent shift of Gi alpha2 to less dense fractions as determined by both Western analysis and [32P]NAD ribosylation catalyzed by pertussis toxin. No such changes were seen in the distribution of Gs alpha or 5'-nucleotidase. Colchicine (100 microM) blocked the GH+Dex-dependent shift of Gi alpha2 from the 16K to the 100K pellet and blocked the lipolytic effects of GH+Dex, but not those of ISO. We conclude that by modifying the relationship between AC and Gi alpha2, GH+Dex relieves some inhibition of cAMP production and consequently increases lipolysis.

Effect of somatotropin, insulin, and glucocorticoid on lipolysis in chronic cultures of adipose tissue from lactating cows

In vitro effects of bovine somatotropin (bST) and insulin plus dexamethasone on lipolysis were evaluated using chronic cultures (48 h) of adipose tissue from lactating cows. Treatments were control (culture medium alone), bST (100 ng/ml), insulin (100 ng/ml) plus dexamethasome (10 nM), and insulin plus dexamethasone plus bST. Following the 48-h cultures, rates of lipolysis were measured in 3-h incubations with isoproterenol (10 microM), adenosine deaminase (0.75 U/ml), and various concentrations of a nonhydrolyzable adenosine analog. The addition of bST to cultures did not alter basal or isoproterenol-stimulated lipolysis. However, the ability of adenosine to inhibit rates of lipolysis was reduced by bST. When measured in the presence of maximal concentrations of adenosine analog, isoproterenol caused an increase in lipolysis above basal, which was twofold greater for explants cultured with insulin plus dexamethasone plus bST than for explants cultured with insulin plus dexamethasone. Dose-response curves for adenosine inhibition of isoproterenol-stimulated lipolysis demonstrated that chronic culture with bST decreased adipose tissue responsiveness and sensitivity to adenosine. Overall, results demonstrated that an in vitro chronic culture system can be used to examine factors that regulate lipolysis. The addition of insulin plus dexamethasone to chronic cultures better maintained the intracellular signaling system, including sensitivity and responsiveness to adenosine inhibition of lipolysis. Results also confirm that bST alters the antilipolytic response to adenosine. Thus, bST effects are in large part due to a relief in the tonic inhibition of lipolysis via changes in the inhibitory G-protein signaling system.

Diverse expression of G-proteins in human sarcoma cell lines with different osteogenic potential: evidence for the involvement of Gi2 in cell proliferation

Previously, it has been shown that the GTP-binding protein Gi2 is implicated in cellular growth [1,2] and differentiation [2,3]. In the present paper we demonstrate that this is also the case for human sarcoma cells. Six human osteosarcoma and three soft tissue sarcoma clonal cell lines were analyzed for levels of G-protein mRNA and polypeptide expression and effector enzyme (i.e., adenylate cyclase and phospholipase C) activation, which were all compared with individual growth rates. Unexpectedly, it appeared that the various strains exhibited large inter-individual variations in G-protein expression and signaling system activation. However, cell doubling time in the exponential phase of growth was inversely correlated (r = 0.71, P < 0.05) to immunodetected levels of intrinsic Gi2 alpha. Furthermore, cells stably transfected with a retroviral (pZipNeo(SV)X) construct containing the activating or inactivating Gi2 alpha-R179E or Gi2 alpha-G204A point mutations consistently reduced or enhanced individual cell strain doubling time, respectively. It appeared that other parameters investigated, including cellular alkaline phosphatase and monoclonal antibody epitope binding, both being markers of the proliferating osteoblast, did not correlate with cell doubling times.

Effect of somatotropin and feed restriction on body composition and adipose metabolism in obese Zucker rats

The objective of the present study was to determine whether exogenous somatotropin (STH) administration in conjunction with feed restriction could alter the composition of gain in the obese rat. Five-week-old female lean and obese Zucker rats were assigned to the following treatments for 6 wk: ad libitum fed (AL), restricted (approximately 75% of AL lean), and restricted with STH (2 mg STH/day). Growth rate was decreased in restricted groups and was normalized to that of the AL lean group in restricted rats treated with STH. In lean rats, restriction decreased protein accretion. Restriction plus STH treatment decreased lipid accretion but increased protein accretion and body weight gain compared with the AL lean group. As expected, feed restriction reduced body size in obese rats, but carcass lipid was maintained at 44%, a level similar to that of the AL obese rats. Lipid accretion rate was decreased with restriction in obese rats and was further reduced, to a level similar to that of the lean group, in the obese rats that were restricted and treated with STH. Protein accretion was decreased in the restricted obese group but was normalized in those treated with STH to a level similar to that in the AL lean group. Basal rates of lipolysis in isolated adipocytes were not affected by STH. However, STH treatment normalized the responsiveness of cells from the obese rats to stimulation of lipolysis by isoproterenol. The results demonstrate that a combination of caloric restriction and STH was effective in normalizing body weight and composition of gain in the obese Zucker rat.

Growth hormone (GH) induces tyrosine-phosphorylated proteins in mouse L cells that express recombinant GH receptors

Porcine and bovine GH receptor (GHR) cDNAs were stably expressed in mouse L cells, which normally do not possess detectable levels of mouse GHR. Expression of the GHR cDNAs resulted in specific binding of 125I-labeled GH by these cell lines. To study GHR-related signaling events in these cells, protein tyrosine phosphorylation was examined. In GH-treated cells, a tyrosine-phosphorylated protein with a molecular mass of approximately 95 kDa (pp95) was increased dramatically (approximately 100-fold) relative to non-GH-treated cells. The amount of pp95 within the cells after GH treatment was positively correlated with the number of GHRs on the cells. Tyrosine phosphorylation of pp95 could not be induced by prolactin, insulin, insulin-like growth factor I, interleukin 2, epidermal growth factor, platelet-derived growth factor, or fibroblast growth factor. Phosphorylation of pp95 was found to be a rapid event that could be observed 60 sec after GH treatment. Also, pp95 appears to exist as a complex of two proteins, i.e., pp95 and pp96. The GH-induced response by these cells may be of use in screening GH analogs for biological activity.